The Multi-Modal Effect of the Anti-fibrotic Drug Pirfenidone on NSCLC

The Multi-Modal Effect of the Anti-fibrotic Drug Pirfenidone on NSCLC

Although immune checkpoint and targeted therapies offer remarkable benefits for lung cancer treatment, some patients do not qualify for these regimens or do not exhibit consistent benefit. Provided that lung cancer appears to be driven by transforming growth factor beta signaling, we investigated th...

Full description

Bibliographic Details
Main Authors: Sebastian Marwitz, Kati Turkowski, Dörte Nitschkowski, Andreas Weigert, Julius Brandenburg, Norbert Reiling, Michael Thomas, Martin Reck, Daniel Drömann, Werner Seeger, Klaus F. Rabe, Rajkumar Savai, Torsten Goldmann
Format: Article
Language:English
Published: Frontiers Media S.A. 2020-01-01
Series:Frontiers in Oncology
Subjects:
TGFβ
lung cancer
immunotherapy
tumor microenvironment
SMAD
Online Access:https://www.frontiersin.org/article/10.3389/fonc.2019.01550/full

Internet

https://www.frontiersin.org/article/10.3389/fonc.2019.01550/full

Similar Items